QIAGEN Reports First Quarter 2012 Results
. - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjust…
. - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjust…
Konzernumsatz steigt um 12% (+13% CER) auf $296,4 Millionen; bereinigtes operatives Ergebnis wächst um 14% auf $80,3 Mil…
. - Both products receive 510(k) clearance for in vitro diagnostic use in the U.S. - Rotor-Gene Q MDx platform offers…
AiCuris announced today that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplan…
. Starkes viertes Quartal 2011: Konzernumsatz steigt um 17% (+17% CER) auf $334,4 Millionen dank zweistelligem Wachstum…
. - Significant progress on strategic initiatives to drive growth and innovation: - Driving platform success: More…
AiCuris announced today that AIC246 (Letermovir), the Company's novel inhibitor against the human cytomegalovirus HCMV,…
Lophius Biosciences, a leading developer of novel T-cell based diagnostic testing systems, today announces the conclusio…
AiCuris announced today that the Food and Drug Administration (FDA) of the United States has granted Fast Track designat…
. - QIAGEN increases offer to shareholders of Cellestis Limited (CST:AU) pursuant to scheme of arrangement - Cellesti…